Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026
Revvity (NYSE: RVTY) reported Q2 CY2026 results. Revenue rose 7.2% year on year to $729.7 million, exceeding analysts’ estimates by 3.2%. Full-year revenue guidance is $2.85 billion at the midpoint, 0.5% above estimates. Non-GAAP EPS was $1.41, 15.9% above consensus.
How this was made
The 30-second read
Why it matters
The article centers on Q2 CY2026 results versus expectations and reiterates full-year revenue guidance at the midpoint, while also emphasizing profitability deterioration via adjusted operating margin contraction.
Market read
Traders can reassess near-term expectations after the reported beat and guidance midpoint, but should weigh the sharp adjusted operating margin decline as a potential drag on multiple expansion.
What to watch
Organic revenue growth is only 3.4% YoY on average over two years, suggesting headline strength may still be influenced by mix, divestitures, or FX rather than broad-based acceleration.
Background
Revvity, formerly PerkinElmer, is a life sciences workflow technology and services provider.
Ticker impact
Revvity reported Q2 CY2026 revenue of $729.7M (+7.2% YoY) and non-GAAP EPS of $1.41, both above analysts’ estimates.
Likely modest positive bias for the stock versus pre-report expectations, with follow-through dependent on whether margin pressure stabilizes.
The article provides concrete earnings and guidance numbers (revenue, EPS, guidance midpoint) and also flags adjusted operating margin contraction to 13.7% in Q2, which can limit the magnitude of any re-rating.
Market effects
Signals demand resilience in life sciences tools/services, but margin compression highlights cost pressure risk for the group.
Primarily US-listed large-cap healthcare/life-sciences sentiment.
Limited direct global spillover beyond read-through to biotech/lab spending expectations.
Counterpoint
The headline beat may be less durable if adjusted operating margin fell sharply and EPS growth is expected to be modest.
Key entities
- companyRevvity
Life sciences company reporting Q2 CY2026 revenue, EPS, and full-year revenue guidance.
- executivePrahlad Singh
CEO who commented on results and signs of increased demand.
